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Abstract
Objective: Low serum 25(OH)D levels are associated with cardiovascular disease (CVD) 
and some of its risk factors. However, in interventional studies, the effects of vitamin D 
supplementation have been uncertain, possibly due to inclusion of vitamin D-sufficient 
subjects. Our aim was therefore to examine effects of vitamin D supplementation on 
CVD risk factors in vitamin D-insufficient subjects.
Design: Double-blinded randomized controlled trial.
Methods: A 4-month interventional study with high-dose vitamin D (100,000 IU loading 
dose, followed by 20,000 IU/week) or placebo with measurements of blood pressure, 
lipids (total-, LDL- and HDL-cholesterol, triglycerides, apolipoproteins A1 and B), and 
glucose metabolism parameters (blood glucose, HbA1c, serum human receptors for 
advanced glycation end products (sRAGE), insulin, C-peptide and HOMA-IR).
Results: A total of 422 subjects with mean serum 25(OH)D level 34 nmol/L were included, 
with 411 subjects completing the study. Serum 25(OH)D levels increased with 56 nmol/L 
and decreased with 4 nmol/L in the vitamin D and placebo group, respectively. We found 
no statistically significant differences between the two groups in any of the measured 
CVD risk factors, except for a minor increase in sRAGE in the vitamin D group. Stratified 
analyses of subjects with low baseline serum 25(OH)D levels alone, or combined with 
blood pressure, lipid and HOMA-IR values above the median for the cohort, did not 
skew the results in favour of vitamin D supplementation.
Conclusion: Supplementation with vitamin D in subjects with baseline vitamin D 
insufficiency does not improve CVD risk factor profile.
Introduction
It is widely acknowledged that the vitamin D receptor 
(VDR), and the enzymes necessary for the hydroxylation 
of vitamin D to 25-hydroxyvitamin D (25(OH)D) and to 
the active form 1,25-dihydroxyvitamin D (1,25(OH)2D) 
are located in most tissues of the body (1). Initially related 
to rickets in children, vitamin D is nowadays considered 
as a vitamin/hormone with multiple functions, such 
as intestinal calcium absorption, involvement in cell 
proliferation and inflammation processes (1). Low 
serum 25(OH)D levels have additionally been related 
to numerous diseases, including cardiovascular disease 
(CVD) and their risk factors (2). Thus, a meta-analysis of 
19 prospective studies focusing on the relation between 
vitamin D status and CVD found a 52% risk increase for 
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future CVD in subjects in the lowest vitamin D category 
(as defined by tertiles, quartiles or arbitrary cut-offs) when 
compared to those in the highest category) (3).
Possible explanatory factors might be the effects of 
vitamin D on CVD risk factors. There are associations 
pointing to an increase in systolic, and to a lesser degree 
diastolic blood pressure with decreasing serum 25(OH)
D levels (4, 5). This may be due to activation of the 
renin-angiotensin system (RAS) as observed in vitamin 
D deficiency (6). Additionally, low serum 25(OH)D 
is associated with increased serum total cholesterol, 
LDL-cholesterol, decreased HDL-cholesterol, high 
apolipoprotein B/apolipoprotein A1 ratio (7, 8), increased 
serum triglycerides (7, 8), as well as reduced insulin 
sensitivity (9, 10). One mechanism for these effects 
could be vitamin D receptor activation related increase 
in CYP7A1, resulting in lowering of cholesterol levels, as 
observed in studies on mice (11).
However, interventional studies have yet to 
demonstrate with certainty effects of vitamin D 
supplementation on CVD risk factors, even when 
examined as meta-analyses. Beveridge et al. included 4541 
participants from 46 randomized controlled trials (RCTs) 
using individual patient data, with no effect on systolic 
or diastolic blood pressure by vitamin D supplementation 
(12). In a meta-analysis by Wang et  al. that included 
12 clinical trials consisting of 1346 participants, no 
beneficial effects on total-cholesterol, HDL-cholesterol 
and triglycerides were found, whereas an increase in LDL-
cholesterol was seen (13). In Challoumas’ review of 19 
relevant RCTs, only one reported benefits of vitamin D 
supplementation on lipid profile parameters, while the 
rest showed no effects or even adverse outcomes (14). In 
a meta-analysis by Poolsup et  al. including 10 trials, no 
effect of vitamin D on insulin resistance was found in 
subjects with pre-diabetes (15). And finally, in a study from 
2017, Seibert et  al. found no effect on CVD risk factors 
with 800 IU vitamin D/day in 105 vitamin D-insufficient 
subjects (16).
However, many of these negative results might be 
explained by inclusion of subjects that were vitamin D 
sufficient, and accordingly, no effect of additional vitamin 
D were to be expected (16, 17). Furthermore, most of the 
studies included in these meta-analyses have been grossly 
underpowered and also complicated by differences in 
vitamin D doses and duration of trials.
In Tromsø, Northern Norway, large population-
based health surveys have been performed with 7- to 
8-year intervals since 1974 (18). In the seventh survey 
in 2015/2016, more than 21,000 subjects were included 
and serum 25(OH)D measured. We therefore had the 
opportunity to invite a large group of subjects known 
to have low serum 25(OH)D levels. The aim of the 
present study was to investigate the effect of vitamin D 
supplementation on cardiovascular risk factors in people 
with known vitamin D insufficiency.
Methods
Subjects
In the seventh survey of the Tromsø study conducted in 
2015/2016, all citizens aged 40 years and above (n = 32,591) 
living in the municipality of Tromsø in northern Norway 
were invited to participate and 21,083 attended (64.7%). 
With serum 25(OH)D successfully measured in 20,922 
participants, 1489 males and females aged <80 years with 
serum values below the 10th percentile (<42 nmol/L) were 
invited by mail to participate in the present study. This 
serum 25(OH)D cut-off was estimated to result in sufficient 
number of participants for the study. A written reminder 
was sent out to non-responders after 2- to 3 weeks’ time. 
All 639 responders were screened by phone by one of the 
study nurses at the Clinical Research Unit at the University 
Hospital of North Norway. This screening included 
questions about medical history to exclude subjects with 
known granulomatous disease, diabetes, renal stones last 
5  years or serious diseases that would make the subject 
unfit for participation, use of vitamin D supplements 
exceeding 800 IU vitamin D per day and use of solarium on 
a regular basis, and subjects who were planning holiday(s) 
in tropical areas during the study period. Women of 
childbearing potential (below the age of 50 years) without 
use of acceptable contraception (hormonal, IUD) were 
excluded. Information about weight, height and smoking 
status was sent to the hospital’s research department for 
use in the randomization procedure.
Study design
Four hundred and fifty-five subjects passed the telephone 
screening and came to the first visit (V1) at the Clinical 
Research Unit at the University Hospital of North Norway. 
The subjects were asked to be fasting overnight, and after 
signing the informed consent, medical history was taken, 
and blood samples were drawn, followed by measurements 
of height and weight (wearing light clothing and no 
shoes) and blood pressure. These examinations revealed 
that 33 subjects were unfit for further participation. The 
remaining 422 subjects then came to the next visit (V2) 
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within 2-5 days. The flow of inclusion is shown in Fig. 1. 
At this second (non-fasting) visit, blood pressure was again 
measured and the study drugs (cholecalciferol capsules 
(20,000 IU (500 µg) Dekristol, Mibe, Jena, Germany) or 
identical looking placebo capsules containing arachis oil 
(Ayanda GmbH & CoKG, Falkenhagen, Germany)) were 
dispensed. As it takes time for serum 25(OH)D levels to 
increase, five capsules were given as a loading dose. The 
weekly dose was based on our previous intervention 
studies where 20,000 IU vitamin D (cholecalciferol) per 
week was sufficient to raise mean serum 25(OH)D levels 
to ~80 nmol/L, whilst not displaying any side effects or 
health risks (19, 20).
The randomization was stratified according to gender, 
vitamin D status in the Tromsø study (serum 25(OH)D 
above/below 25 nmol/L), smoking status and body mass 
index (BMI) above/below 27 kg/m2 (self-reported height 
and weight). Age was not used in the randomization 
process. Based on this, the randomization unit assigned 
the subject a randomization number using a block 
randomization procedure. This randomization number 
was sent to the Clinical Research Unit for registration and 
to the hospital’s pharmacy who dispensed the medication 
accordingly. Except for the pharmacy, which had no 
contact with the study participants, all nurses, doctors and 
other study personnel were blinded to the randomization 
throughout the study.
Two months after the first visit, the subjects were 
contacted by one of the study nurses, asked for adverse 
events and reminded to take the study medication. Two 
months thereafter, the third visit (V3) was performed 
with examinations identical to V1. The fourth visit (V4) 
followed a few days later, with return of study medication 
and the additional blood pressure measurements. 
Compliance was calculated as the ratio of capsules used 
(capsules supplied minus capsules returned) to number of 
weeks between V2 and V4.
The subjects were asked not to take any vitamin D 
supplements (including cod liver oil) during the 4-month 
intervention period. At the end of the study, all subjects 
(regardless of randomization) were advised vitamin D 
supplementation 800 IU per day.
Measurements
BMI was calculated as weight (kg) divided by squared 
height (m²). Blood pressure was measured after 15 min 
of rest with an automatic device (AND, A&D Medical, 
Tokyo, Japan) three times with 2 min apart. The baseline 
(and similarly the end of study) blood pressure was 
calculated as ((median BP from V1) + (median BP from 
V2))/2. Serum calcium was analysed by an automated 
analyser (Modular P, Roche Diagnostics, Mannheim, 
Germany) with reagents from Boehringer Mannheim 
and a modified Jaffe reaction (Roche Hitachi 911) was 
used for measurement of serum creatinine. Intact 
parathyroid hormone (PTH) was analysed with an 
electrochemiluminescence immunoassay (ECLIA) 
using an automated clinical chemistry analyser (Cobas 
6000, Roche). Serum cholesterol, HDL-cholesterol, 
LDL-cholesterol and triglycerides were analysed with 
enzymatic colorimetric methods using an automated 
analyser (Cobas 8000, Roche), and apolipoprotein 
A1 and apolipoprotein B were analysed by immune 
turbidimetry (Cobas 8000, Roche). Insulin and C-peptide 
Figure 1
Flowchart for the inclusion and performance of the study.
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were analysed by immunometry (Cobas 8000, Roche), 
whereas glucose was measured by photometry (Cobas 
8000, Roche). HbA1c was measured by high-performance 
liquid chromatography using a Tosho G8, Tokyo, Japan. 
Serum concentrations of 25(OH)D were measured by 
an in-house liquid chromatography–tandem mass 
spectrometry method that detects both 25(OH)D3 and 
25(OH)D2 and the sum of these presented as 25(OH)D 
in the results (21). The coefficient of variation (CV) for 
both assays is <2%. Serum human receptors for advanced 
glycation end products (extracellular domain) (sRAGE) 
was measured using ELISA kits (Quantikine, R&D 
Systems) according to the manufacturer’s instructions 
at the Hormone Laboratory, Oslo University Hospital. 
The inter-assay CV in our laboratory was 5.8% (22). 
Insulin sensitivity was assessed with the homeostasis 
model (HOMA-IR) ((insulin (pmol/L) × (glucose 
(mmol/L))/135) (23).
Statistical analysis
All variables were examined for normality of distribution, 
with analysis of skewness and kurtosis, visual inspection 
of histograms, P-P and Q-Q plots. Of the dependent 
variables HDL-cholesterol, triglycerides, PTH, insulin, 
C-peptide and HOMA-IR were not normally distributed 
at baseline, but were successfully corrected with log 
transformation and used as such in the statistical analyses. 
For delta values (value at end of study minus value at 
baseline), triglycerides, HOMA-IR and insulin had non-
normal distribution and could not be normalized by log 
transformation.
At baseline, comparison between the vitamin D and 
placebo groups was performed by Student’s t-test for 
independent samples. The effect of the intervention was 
analysed per-protocol by a general linear regression model 
with the delta value as dependent variable, and age, gender, 
baseline value and randomization status as covariates. For 
delta triglycerides, insulin and HOMA-IR, the delta values 
were compared with Mann–Whitney U test. Interactions 
between baseline values and randomization status were 
tested by including the baseline values (dichotomous, 
median-split) in the unadjusted regression models. 
P values <0.10 of the interaction term were considered 
statistically significant.
Normally distributed data are presented as mean 
(SD), non-normally distributed values as median (5th, 
95th percentiles). P < 0.05 was considered statistically 
significant and all tests were done two-sided. IBM SPSS 
Statistics version 24 was used for the statistical analysis.
Power calculation
The main endpoints in the study were effects on the 
cardiovascular risk factors blood pressure, serum lipids 
and insulin resistance. The power calculation was made 
on the assumption that those included would have a 
mean serum 25(OH)D of 30 nmol/L and that those given 
vitamin D would have an increase in serum 25(OH)D to a 
mean level of 80 nmol/L. We assumed that the maximal, 
realistic effect of the vitamin D supplementation would be 
two-third of the difference in systolic and diastolic blood 
pressure, serum triglycerides and HDL-cholesterol and 
insulin resistance (as evaluated by HOMA-IR) between 
those with serum 25(OH)D levels of ~30 pmol/L and 
~80 nmol/L found in cross-sectional studies (4, 7). Thus, 
if wanting a power of 0.8 and P < 0.05, we would need 450 
subjects to show an effect of 6.7 mmHg on systolic blood 
pressure, 410 subjects for 3.3 mmHg on diastolic blood 
pressure, 300 subjects for 0.26 mmol/L on triglycerides, 
490 subjects for 0.09 mmol/L on HDL-cholesterol and 400 
subjects for 0.57 on HOMA-IR. Based on this, we would 
need ~500 subjects to complete the intervention to have a 
reasonable chance of demonstrating the anticipated effect 
on the primary endpoints. We assumed a dropout rate of 
16%, and therefore aimed to include 600 subjects in the 
study.
Ethics
All participants signed an informed consent form after 
receiving oral and written information on the study design, 
aim and duration. The subjects received a gift card value 
200 NKR (20 Euro) to cover travel expenses in the study. 
The study was approved by the Regional Committee for 
Medical Research Ethics (REK NORD 2013/1464) and by 
the Norwegian Medicines Agency (2013-003514-40). The 
study is registered at ClinicalTrials.gov NCT02750293.
Results
The characteristics of the 422 subjects (224 men and 198 
women) who fulfilled all inclusion criteria and came to V2 
are shown in Table 1; mean age of 50 years, BMI 28 kg/m2 
and serum 25(OH)D 34 nmol/L. One hundred and ten 
subjects were included during the summer months 
May–August and 312 subjects during September–March 
(when there is no effective UV radiation at our latitude). 
At baseline, the vitamin D group (n = 211) and the placebo 
group (n = 211) did not differ significantly except for a 
slight difference in serum creatinine (Table 1).
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Two hundred and eight subjects in the vitamin D 
group and 203 in the placebo group completed the study. 
The compliance rate was very high; 15% of the subjects 
had a compliance rate between 84 and 100%, and the rest 
a compliance rate of 100% or higher.
In the vitamin D group, mean serum 25(OH)D levels 
increased to 88.7 nmol/L, whereas there was a slight 
decrease in the placebo group to 30.6 nmol/L. Except for a 
decrease in serum PTH and an increase in serum creatinine 
in the vitamin D group, there were no significant changes 
in any of the measured parameters between the vitamin D 
and the placebo groups at the end of the study (Table 2). 
Thirty subjects in the vitamin D group and 36 subjects 
in the placebo group used blood pressure–lowering 
drugs, and 16 and 32 subjects used lipid-lowering drugs, 
respectively. The lack of effect on blood pressure and 
lipids was seen also when subjects using blood pressure– 
or lipid-lowering drugs were excluded (data not shown).
Subgroup analyses
Effect of baseline and end of study serum 25(OH)D
Subgroup analyses on subjects with baseline serum 25(OH)
D <40 nmol/L, and for those in the vitamin D group with 
end of study serum 25(OH)D >70 nmol/L (n = 136) and 
those in the placebo group with end of study 25(OH)D 
<40 nmol/L (n = 127) were performed. In this subgroup 
there were again significant differences in delta values 
for serum PTH and creatinine. In addition, delta sRAGE 
was significantly (P < 0.05) higher in the vitamin D group, 
whereas no significant difference was found for the other 
delta values (Table 3). Further analysis with lowering the 
cut-off baseline value to 30 nmol/L was also performed (87 
subjects in the vitamin D and 77 subjects in the placebo 
group), which yielded similar results (data not shown).
Effects of baseline blood pressure, baseline serum 
lipids and baseline HOMA-IR
There were no significant interactions between baseline 
levels of blood pressure, serum lipids and HOMA-IR 
and randomization status in regard to the delta values. 
To further explore if subjects more exposed to the risk 
factors would benefit from vitamin D supplementation, 
separate analyses were made in subjects with baseline 
level of the risk factor above the median for the cohort 
(or below for HDL-cholesterol and apolipoprotein A1) 
combined with baseline serum 25(OH)D <40 nmol/L and 
the expected end of study response in serum 25(OH)D. 
However, this did not show any significant benefit from 
the vitamin D supplementation (Supplementary Table 1, 
see section on supplementary data given at the end of 
this article).
Side effects
No serious study-related side effects were recorded. 
Two subjects developed hypercalcemia (serum 
calcium = 2.57 mmol/L); one male whose serum calcium 
normalized upon re-testing, and one female who was 
found to have developed primary hyperparathyroidism.
Discussion
To summarize, we found no significant effect of 4-month 
vitamin D supplementation on blood pressure, serum 
lipids, insulin resistance or other cardiovascular risk 
factors, regardless of baseline serum 25(OH)D levels and 
Table 1 Baseline characteristics of all subjects randomized.
Vitamin D Placebo
Count 211 211
Sex (male %) 53.1 53.1
Age (years) 50 (41, 68) 51 (41, 70)
Smoking (%) 21.8 21.3
Serum 25(OH)D (nmol/L) 32.9 (11.7) 35.4 (13.9)
BMI (kg/m2) 27.9 (5.1) 27.8 (4.7)
Systolic BP (mmHg) 122 (13) 123 (12)
Diastolic BP (mmHg) 77 (9) 77 (9)
Serum creatinine (μmol/L) 70.5 (11.8)* 72.5 (13.1)
Serum calcium (mmol/L) 2.27 (0.07) 2.27 (0.07)
Serum PTH (pmol/L) 6.2 (4.1, 11.2) 6.6 (4.3, 10.4)
Serum triglycerides 
(mmol/L)
1.20 (0.60, 2.80) 1.10 (0.60, 2.50)
Serum cholesterol (mmol/L) 5.22 (0.97) 5.13 (0.96)
Serum LDL-cholesterol 
(mmol/L)
3.54 (0.90) 3.45 (0.91)
Serum HDL-cholesterol 
(mmol/L)
1.30 (0.90, 2.20) 1.40 (0.80, 2.20)
Serum apolipoprotein A1 
(mmol/L)
1.50 (0.25) 1.50 (0.27)
Serum apolipoprotein B 
(mmol/L)
1.10 (0.28) 1.07 (0.27)
Blood glucose (mmol/L) 5.45 (0.52) 5.49 (0.56)
HbA1c (%) 5.49 (0.31) 5.49 (0.31)
Serum insulin (pmol/L) 67 (27, 207) 68 (23, 189)
Serum C-peptide (pmol/L) 836 (443, 1645) 819 (412, 1666)
Serum sRAGE (pg/mL) 1239 (469) 1169 (445)
HOMA-IR 2.70 (1.00, 8.48) 2.84 (0.86, 8.15)
Data are shown as prevalence or as mean (s.d.) for normally distributed 
data, and median (5th, 95th percentiles) for non-normal data.
*P < 0.05, Student’s t-test.
25(OH)D, cholecalciferol; BMI, body mass index; BP, blood pressure; 
HbA1c, glycosylated haemoglobin; HOMA-IR, Homeostatic Model 
Assessment for Insulin Resistance; PTH, parathyroid hormone; sRAGE, 
serum human receptors for advanced glycation end products.
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risk factors profile. This is in agreement with the recently 
published study by Seibert et al. (16).
The indications for an association between vitamin 
D and CVDs and their risk factors are substantial. There 
are numerous prospective, observational studies showing 
these relations, and their corresponding meta-analyses 
and systematic reviews are all confirmative (3, 12, 13, 14, 
15, 24). Furthermore, the vitamin D receptor is found in 
blood vessels, as well as in beta-cells and adipocytes (1), 
and effect of vitamin D on the RAS has been demonstrated 
in experimental animals (6). However, showing a causal 
relationship in interventional trials has been difficult, 
which could be explained by underpowered studies and 
not including subjects with vitamin D insufficiency (serum 
25(OH)D <50 nmol/L) or deficiency (serum 25(OH)D 
<30 nmol/L), as defined by the Institute of Medicine (20).
To account for this, we invited a large group of subjects 
with low serum 25(OH)D levels, and still the results were 
negative, with no improvement in the cardiovascular risk 
factors profile. Since we included subjects based on serum 
25(OH)D levels measured up to 2 months prior to start 
of the study, some subjects had serum 25(OH)D levels 
>40 nmol/L at baseline. However, even when restricting 
the analyses to subjects with baseline serum 25(OH)
D levels <40 nmol/L (or even <30 nmol/L) and with the 
expected increase in serum 25(OH)D in the vitamin D 
group and lack of increase in the placebo group, there was 
no improvement in the results in favour of vitamin D.
If lack of vitamin D is causally related to a definite risk 
factor, it is reasonable to believe that supplementation 
would be most efficient in the subjects with the highest 
risk level. To explore this, we examined potential 
interactions between baseline level of the risk factors 
and randomization status regarding the outcomes, 
but found no such interactions. Furthermore, we did 
stratified analyses of subjects with blood pressure, lipid 
and HOMA-IR values above the median for the cohort, 
combined with low baseline serum 25(OH)D; but again, 
no significant effects of vitamin D were found.
Previous studies on vitamin D and lipid and glucose 
metabolism have generally included standard measures like 
triglycerides and cholesterols, glucose, insulin and HbA1c. 
Table 2 Baseline characteristics and delta values (end of study value minus baseline) in those of the vitamin D and placebo 
group who completed the study.
 Baseline Delta values
Vitamin D Placebo Vitamin D Placebo
Count 208 203 208 203
Sex (male %) 53.4 53.2
Age (years) 50 (41, 67) 51 (41, 70)
Smoking (%) 22.1 22.2
Serum 25(OH)D (nmol/L) 32.6 (11.1) 35.1 (13.6) 56.2 (22.1)** −4.5 (12.8)
BMI (kg/m2) 27.9 (5.1) 27.8 (4.7) 0.18 (0.68) 0.12 (0.70)
Systolic BP (mmHg)*** 122 (13) 123 (13) 0.2 (7.8) −0.9 (7.2)
Diastolic BP (mmHg)*** 77 (9) 77 (9) 0.4 (4.8) −0.5 (4.6)
Serum creatinine (μmol/L) 70.5 (11.8)* 72.6 (13.3) 1.0 (5.8)* −0.1 (5.1)
Serum calcium (mmol/L) 2.27 (0.07) 2.27 (0.07) 0.01 (0.07) 0.00 (0.06)
Serum PTH (pmol/L) 6.2 (4.1, 11.2) 6.68 (4.3, 10.4) −0.76 (1.39)** 0.54 (1.49)
Serum triglycerides (mmol/L)**** 1.20 (0.60, 2.60) 1.10 (0.60, 2.50) 0.00 (−0.50, 0.90) 0.00 (−0.60, 0.70)
Serum cholesterol (mmol/L)**** 5.22 (0.95) 5.15 (0.95) 0.11 (0.52) 0.03 (0.58)
Serum LDL-cholesterol (mmol/L)**** 3.55 (0.89) 3.46 (0.91) 0.11 (0.51) 0.04 (0.53)
Serum HDL-cholesterol (mmol/L)**** 1.30 (0.90, 2.20) 1.35 (0.80, 2.20) −0.02 (0.18) −0.01 (0.16)
Serum apolipoprotein A1 (mmol/L)**** 1.50 (0.25) 1.50 (0.28) −0.03 (0.15) −0.03 (0.15)
Serum apolipoprotein B (mmol/L)**** 1.10 (0.28) 1.07 (0.27) 0.04 (0.15) 0.04 (0.15)
Blood glucose (mmol/L) 5.45 (0.51) 5.50 (0.56) 0.02 (0.41) −0.02 (0.40)
HbA1c (%) 5.49 (0.31) 5.50 (0.32) 0.04 (0.15) 0.03 (0.15)
Serum insulin (pmol/L) 67 (27, 199) 69 (23, 189) 4 (−45, 59) 3 (−51, 78)
Serum C-peptide (pmol/L) 838 (450, 1644) 833 (412, 1666) 43 (205) 4 (216)
Serum sRAGE (pg/mL) 1230 (465) 1167 (451) 145 (267) 108 (289)
HOMA-IR 2.70 (1.00, 8.43) 2.89 (0.86, 8.15) 0.15 (−2.03, 2.61) 0.11 (−2.73, 3.30)
Data are shown as prevalence, mean (s.d.) for normally distributed data, and median (5th, 95th percentiles) for non-normal data.
*P < 0.05, **P < 0.01 vs placebo group. For baseline values, Student’s t-test, for delta values linear regression with age, gender and baseline value as 
covariates; ***Two subjects in the vitamin D and four subjects in the placebo group excluded due to change in use of blood pressure medication during 
the study; ****Three subjects in the vitamin D and one subject in the placebo group excluded due to change in use of lipid-lowering medication during 
the study.
25(OH)D, cholecalciferol; BMI, body mass index; BP, blood pressure; HbA1c, glycosylated haemoglobin; HOMA-IR, Homeostatic Model Assessment for 
Insulin Resistance; PTH, Parathyroid Hormone; sRAGE, serum human receptors for advanced glycation end products.
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Recently, it has been shown that apolipoprotein A1 and 
apolipoprotein B might be as good or even better than the 
standard lipid parameters for the evaluation of the risk 
of future myocardial infarction (25). Similarly, sRAGE, 
which is the soluble receptor for advanced glycation end 
products and may thus block/counteract their detrimental 
inflammatory effects (26), may reflect other aspects of 
glucose metabolism than HbA1c and HOMA-IR, and has 
in one study been reported to increase with vitamin 
D supplementation (27). These measurements were 
therefore included in our study, and for sRAGE, there was 
a significant increase in the vitamin D compared to the 
placebo group when the analysis was restricted to those 
with low baseline serum 25(OH)D. The difference was 
modest and should be interpreted accordingly. However, 
if confirmed in other studies, a relation between vitamin 
D and sRAGE could potentially be of importance for 
prevention of CVD diseases.
The main source of vitamin D is solar UV radiation, 
and select dietary sources like fatty fish, but the serum 
level of 25(OH)D is also affected by genetic factors (28). 
There are several single-nucleotide polymorphisms (SNPs) 
related to the serum 25(OH)D level, and if these SNPs are 
also related to the CVD risk factors, that would indicate 
a causal relationship. Another approach for evaluating 
the effect of vitamin D on the risk factors would therefore 
be Mendelian randomization analyses. For vitamin D 
and blood pressure, Vimaleswaran et  al. used a genetic 
25(OH)D synthesis score in a combined cohort of 146,581 
subjects and found that for each risk allele (out of four), 
there was a slight, but significant increase of 0.10 mmHg in 
systolic blood pressure and 0.08 mmHg in diastolic blood 
pressure (29). On the other hand, low 25(OH)D levels did 
not associate genetically with levels of remnant and LDL-
cholesterol in a Danish study on 31,345 subjects (30). 
However, even results from Mendelian randomization 
analyses should be viewed with caution as the genes 
involved may not only affect serum 25(OH)D, but the 
production of other metabolites as well. The relation to 
serum 25(OH)D could also simply be co-variation since the 
vitamin D SNPs could be linked to other SNPs that truly 
have the effects in question. In spite of these limitations, 
Table 3 Subgroup baseline and delta values for subjects with serum 25(OH)D baseline values <40 nmol/L and end of study values 
>70 nmol/L for the vitamin D group and <40 nmol/L for the placebo group.
 Baseline Delta values
Vitamin D Placebo Vitamin D Placebo
Count 136 127 136 127
Sex (male %) 47.1 51.2
Age (years) 49 (41, 66) 51 (41, 70)
Smoking (%) 25.0 26.8
Serum 25(OH)D (nmol/L) 28.0 (6.7) 27.9 (6.7) 65.9 (18.7) −1.7 (7.0)
BMI (kg/m2) 27.5 (4.9) 28.1 (4.9) 0.16 (0.69) 0.08 (0.69)
Systolic BP (mmHg) 121 (13) 124 (12) −0.3 (7.6) −0.6 (7.3)
Diastolic BP (mmHg) 76 (9) 77 (8) 0.15 (4.6) −0.8 (4.3)
Serum creatinine (μmol/L) 70.8 (11.6) 71.6 (11.6) 1.0 (5.5)* −0.3 (5.0)
Serum calcium (mmol/L) 2.27 (0.07) 2.27 (0.08) 0.01 (0.07) 0.0 (0.06)
Serum PTH (pmol/L) 6.4 (4.0, 10.7) 6.8 (4.3, 11.0) −0.81 (1.34)** 0.50 (1.57)
Serum triglycerides (mmol/L) 1.20 (0.60, 2.60) 1.20 (0.60, 2.60) 0.00 (−0.60, 0.90) 0.00 (−0.80, 0.70)
Serum cholesterol (mmol/L) 5.27 (0.89) 5.08 (0.93) 0.05 (0.45) 0.05 (0.52)
Serum LDL-cholesterol (mmol/L) 3.57 (0.82) 3.42 (0.88) 0.06 (0.41) 0.04 (0.46)
Serum HDL-cholesterol (mmol/L) 1.40 (0.90, 2.30) 1.30 (0.80, 2.10) −0.01 (0.19) 0.01 (0.15)
Serum apolipoprotein A1 (mmol/L) 1.54 (0.26) 1.47 (0.29) −0.03 (0.15) −0.02 (0.13)
Serum apolipoprotein B (mmol/L) 1.10 (0.25) 1.08 (0.27) 0.04 (0.13) 0.04 (0.13)
Blood glucose (mmol/L) 5.41 (0.47) 5.49 (0.58) 0.04 (0.41) −0.01 (0.38)
HbA1c (%) 5.47 (0.28) 5.49 (0.32) 0.05 (0.15) 0.05 (0.15)
Serum insulin (pmol/L) 58 (24, 164) 71 (25, 189) 3.0 (−32, 54) 2.0 (−50, 96)
Serum C-peptide (pmol/L) 788 (433, 1477) 831 (410, 1681) 47 (198) 11 (201)
Serum sRAGE (pg/mL) 1217 (460) 1211 (482) 156 (274)* 80 (300)
HOMA-IR 2.31 (0.84, 7.41) 2.89 (0.96, 8.54) 0.15 (−1.45, 2.41) 0.11 (−2.93, 4.18)
Data are shown as prevalence, mean (s.d.) for normally distributed data, and median (5th, 95th percentiles) for non-normal data.
*P < 0.05, **P < 0.01 vs placebo group, linear regression with age, gender and baseline value as covariates; ***One subjects in the vitamin D and four 
subjects in the placebo group excluded due to change in use of blood pressure medication during the study; ****One subject in the vitamin D group 
excluded due to change in use of lipid lowering medication during the study.
25(OH)D, cholecalciferol; BMI, body mass index; BP, blood pressure; HbA1c, glycosylated haemoglobin; HOMA-IR, Homeostatic Model Assessment for 
Insulin Resistance; PTH, parathyroid hormone; sRAGE, serum human receptors for advanced glycation end products.
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the lack of/or minor effect in Mendelian randomization 
studies give strong support to the results from the clinical 
intervention studies.
CVD risk factors are surrogate endpoints for clinical 
disease, and the true test of benefit from vitamin D 
supplementation is of course prevention of disease 
and reduction in mortality. One large RCT testing this, 
the ViDa study from New Zealand that included 5110 
subjects, has recently been published and found no effect 
on cardiovascular events (31). Several other large vitamin 
D RCTs are ongoing, with results expected within a few 
years (32, 33). Unfortunately, even these large studies 
might not give the definite answer as most of the subjects 
included probably are vitamin D sufficient (34). Therefore, 
large RCTs with inclusion of vitamin D-deficient subjects 
and surrogate endpoint, like our study, are of importance.
Our study has several limitations. We aimed to 
include 600 subjects with a mean serum 25(OH)D of 
30 nmol/L, but were only able to include 422 subjects 
with a mean serum 25(OH)D level of 34 nmol/L. However, 
we find it unlikely that inclusion of 200 more subjects 
would have changed the results in favour of the vitamin 
D supplementation as none of the observations were 
even close to reach statistical significance. Similarly, we 
find it unlikely that our negative results were due to the 
inclusion of subjects with slightly higher serum 25(OH)
D levels than anticipated, as sub-group analyses based on 
baseline as well as on final serum 25(OH)D levels did not 
change the results in favour of vitamin D.
Although we could invite the subjects with the 
lowest serum 25(OH)D levels in a population-based study 
including more than 21,000 subjects, only 12 of our 
subjects had serum 25(OH)D <15 nmol/L. We therefore 
cannot exclude effects on the risk factors in subjects 
with more profound vitamin D deficiency. We did 
stratified analyses on the subjects with high risk factors 
combined with low serum 25(OH)D levels (which is the 
ideal groups to study), but such stratification reduced 
the number of subjects considerably and accordingly, 
the statistical power was limited. The intervention time 
was only 4 months, and we cannot rule out that a longer 
intervention (in particular for insulin resistance that 
is strongly related to body weight) might have given 
different results. We used weekly doses, where daily 
doses that result in not only elevated serum 25(OH)D 
levels, but also increased serum cholecalciferol levels, 
would possibly be more biologically efficient (35). 
Furthermore, it might have been better if the entire 
study had been performed during the winter months to 
avoid endogenous synthesis of vitamin D in the skin. 
Additionally, there are findings that suggest people 
may have varying molecular responses to vitamin D 
and therefore may need different supplementation/
intervention doses. This has been conceptualized as 
a personal vitamin D response index, based on the 
epigenetic response and gene transcription following 
vitamin D supplementation (36). We did not have that 
information available for our participants, but might be 
relevant to include in future studies.
On the other hand, our study has also several 
strengths. The expected fall in serum PTH in the vitamin 
D group provided our study an intern validity. Our RCT 
is, to our knowledge, the largest conducted RCT so far in 
vitamin D-insufficient and -deficient subjects with change 
in CVD risk factors profile as primary endpoint. The study 
was performed with strict adherence to RCT rules, and 
the vitamin D dose given was sufficient to increase serum 
25(OH)D levels adequately. Moreover, we used blood 
pressure measurements from 2  days both at start and 
end of the study and included a wide range of lipid and 
glucose metabolism parameters, and the dropout rate was 
low and the compliance high.
The association between serum 25(OH)D levels and 
CVD risk factors in observational studies is most likely 
due to confounding factors, as we have previously 
reported for serum lipids based on cross-sectional data 
(37). In addition, there is always a high probability of 
reverse causation for vitamin D and health; good health 
(which is associated with health predictors like blood 
pressure, lipids and glucose metabolism) probably allows 
people to stay more outdoors and get increased sun 
exposure, and is therefore the driver of the vitamin D 
association.
In conclusion, vitamin D supplementation does not 
improve the cardiovascular risk factors blood pressure, 
lipids or insulin resistance, with the possible exception of 
serum sRAGE. This does not exclude an effect in those 
with severe vitamin D deficiency, but these subjects 
should be treated with vitamin D for skeletal health 
reasons regardless of CVD risk factors.
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